Proxima

Name: Proxima
Brand: Proxima

Unlock profitable growth with predictive data intelligence

Est 2019|Raised $12M

LinkedIn 12K|Web traffic 1K|FTEs 75|HQ New York, New York, US

01Competitive Landscape

Narrative analysis

- Where Proxima may be positioned to add value: If NeoLink meaningfully increases the scale of interaction and structural restraint data and if Neo-1 can reliably assemble sparse restraints, the combination could enable exploration of induced proximity design spaces that are otherwise difficult to access. - Where competitors may have advantages: - Arvinas: public-company transparency and progression of clinical-stage assets. - C4 Therapeutics: established platform messaging and a clearer public reporting environment due to public-company disclosures. - Kymera / Nurix: existing pharma partnerships and internal pipelines that could demonstrate repeatability of outputs.

Adoption / market signals

Reported seed funding and participation from venture investors indicate investor interest in the company and approach.
The Halda alliance indicates external partner interest, but does not by itself confirm repeatable scientific output.

	Proxima (company website)	C4 Therapeutics	Arvinas
Starting Price	Not disclosed (platform biotech partnerships)	N/A (public biotech; platform + pipeline)	N/A (public biotech; pipeline)
Intended partners / Best-fit customers	Partners seeking a combined experimental data and computational modeling approach for proximity modulators / molecular glues	Organizations pursuing degrader discovery with C4’s TORPEDO® platform and collaborations	Organizations focused on clinical-stage PROTAC programs; modality-focused development
Key Strength	Coupling XLMS-derived structural restraint generation (NeoLink) with an atomistic modeling approach (Neo-1); a proposed data feedback loop between experiment and model	Established platform branding (TORPEDO®) and public-company disclosure environment	Clinical-stage assets demonstrating modality execution in humans
Key Weakness	Limited independent validation publicly; few public outcome reports; limited public security/compliance documentation	Platform outcomes remain subject to standard biotech clinical and development risks	Modality focus may be narrower than approaches that target a broader set of proximity interactions; still subject to clinical and translational risk

01Competitive Landscape

Narrative analysis

Where Proxima may be positioned to add value: If NeoLink meaningfully increases the scale of interaction and structural restraint data and if Neo-1 can reliably assemble sparse restraints, the combination could enable exploration of induced proximity design spaces that are otherwise difficult to access.
Where competitors may have advantages:
- Arvinas: public-company transparency and progression of clinical-stage assets.
- C4 Therapeutics: established platform messaging and a clearer public reporting environment due to public-company disclosures.
- Kymera / Nurix: existing pharma partnerships and internal pipelines that could demonstrate repeatability of outputs.

Adoption / market signals

Reported seed funding and participation from venture investors indicate investor interest in the company and approach.
The Halda alliance indicates external partner interest, but does not by itself confirm repeatable scientific output.

	Proxima (company website)	C4 Therapeutics	Arvinas
Starting Price	Not disclosed (platform biotech partnerships)	N/A (public biotech; platform + pipeline)	N/A (public biotech; pipeline)
Intended partners / Best-fit customers	Partners seeking a combined experimental data and computational modeling approach for proximity modulators / molecular glues	Organizations pursuing degrader discovery with C4’s TORPEDO® platform and collaborations	Organizations focused on clinical-stage PROTAC programs; modality-focused development
Key Strength	Coupling XLMS-derived structural restraint generation (NeoLink) with an atomistic modeling approach (Neo-1); a proposed data feedback loop between experiment and model	Established platform branding (TORPEDO®) and public-company disclosure environment	Clinical-stage assets demonstrating modality execution in humans
Key Weakness	Limited independent validation publicly; few public outcome reports; limited public security/compliance documentation	Platform outcomes remain subject to standard biotech clinical and development risks	Modality focus may be narrower than approaches that target a broader set of proximity interactions; still subject to clinical and translational risk

Proxima

01Competitive Landscape

Narrative analysis

Adoption / market signals

02Market Map

01Competitive Landscape

Narrative analysis

Adoption / market signals

02Market Map